McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D. authored a DDN News article dated May 2020 entitled, “Are things looking up for subject matter eligibility in the life sciences?.” The recent history of subject matter eligibility in the life sciences before the Court of Appeals for the Federal Circuit has been fraught with uncertainty, and the most recent decision, in Illumina, Inc. v. Ariosa Diagnostics, Inc., illustrates this uncertainty nicely (particularly because a divided panel of the Court held that the claims were eligible for patenting. view the article